Novartis Designs “Arogya Parivar” To Reach Real India In Its Rural Centers
This article was originally published in PharmAsia News
MUMBAI - Swiss drug maker Novartis recently launched its ace anti-diabetes drug Galvus in India to take Merck's Januvia head on, but the company's larger focus seems to be shifting fast from the mega cities to the rural market where "real India lives.
You may also be interested in...
India’s northeast combines a rural population that lacks access to basic health care in many cases in terrain dissected by rivers, jungles and mountains. The World Bank has identified funding several models of sustainable and scalable health care delivery for start-ups that transcend such barriers.
Novartis Stays Firm On India Plans After Gleevec: An Interview With India Vice Chairman Ranjit Shahani
Novartis has been at the center of a long patent controversy, and although it recently faced an adverse ruling, India Vice Chairman Ranjit Shahani’s optimism about the Indian market is unshaken.
MUMBAI - For many years Swiss pharmaceutical giant Novartis voiced reservations about certain provisions of the Indian patent laws and data exclusivity issues, but the maker of Glivec (imatinib) looks set to introduce its next-line therapy for chronic myeloid leukemia Tasigna (nilotinib) into the Indian market